These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 11504907)
1. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Podsypanina K; Lee RT; Politis C; Hennessy I; Crane A; Puc J; Neshat M; Wang H; Yang L; Gibbons J; Frost P; Dreisbach V; Blenis J; Gaciong Z; Fisher P; Sawyers C; Hedrick-Ellenson L; Parsons R Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10320-5. PubMed ID: 11504907 [TBL] [Abstract][Full Text] [Related]
2. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908 [TBL] [Abstract][Full Text] [Related]
3. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656 [TBL] [Abstract][Full Text] [Related]
4. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639 [TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757 [TBL] [Abstract][Full Text] [Related]
6. The biology and clinical relevance of the PTEN tumor suppressor pathway. Sansal I; Sellers WR J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063 [TBL] [Abstract][Full Text] [Related]
7. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Kwon CH; Zhu X; Zhang J; Baker SJ Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12923-8. PubMed ID: 14534328 [TBL] [Abstract][Full Text] [Related]
8. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Han S; Khuri FR; Roman J Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245 [TBL] [Abstract][Full Text] [Related]
9. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285 [TBL] [Abstract][Full Text] [Related]
10. Constitutive cellular expression of PI 3-kinase is distinct from transient expression. Auger KR; Wang J; Narsimhan RP; Holcombe T; Roberts TM Biochem Biophys Res Commun; 2000 Jun; 272(3):822-9. PubMed ID: 10860837 [TBL] [Abstract][Full Text] [Related]
11. Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Shao J; Evers BM; Sheng H Cancer Res; 2004 Jan; 64(1):229-35. PubMed ID: 14729629 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1. El-Chaâr D; Gagnon A; Sorisky A Int J Obes Relat Metab Disord; 2004 Feb; 28(2):191-8. PubMed ID: 14970836 [TBL] [Abstract][Full Text] [Related]
13. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Wu L; Birle DC; Tannock IF Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283 [TBL] [Abstract][Full Text] [Related]
14. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Hu X; Pandolfi PP; Li Y; Koutcher JA; Rosenblum M; Holland EC Neoplasia; 2005 Apr; 7(4):356-68. PubMed ID: 15967113 [TBL] [Abstract][Full Text] [Related]
15. Insulin-induced Drosophila S6 kinase activation requires phosphoinositide 3-kinase and protein kinase B. Lizcano JM; Alrubaie S; Kieloch A; Deak M; Leevers SJ; Alessi DR Biochem J; 2003 Sep; 374(Pt 2):297-306. PubMed ID: 12841848 [TBL] [Abstract][Full Text] [Related]
16. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630 [TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Panwalkar A; Verstovsek S; Giles FJ Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419 [TBL] [Abstract][Full Text] [Related]
18. Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production. Salh B; Wagey R; Marotta A; Tao JS; Pelech S J Immunol; 1998 Dec; 161(12):6947-54. PubMed ID: 9862729 [TBL] [Abstract][Full Text] [Related]
19. Restraining PI3K: mTOR signalling goes back to the membrane. Harrington LS; Findlay GM; Lamb RF Trends Biochem Sci; 2005 Jan; 30(1):35-42. PubMed ID: 15653324 [TBL] [Abstract][Full Text] [Related]
20. IL2-dependent phosphorylation of 40S ribosomal protein S6 is controlled by PI-3K/mTOR signalling in CTLL2 cells. Tuhácková Z; Sloncová E; Vojtechová M; Sovová V Int J Mol Med; 2004 Apr; 13(4):601-5. PubMed ID: 15010863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]